HER2-POSITIVE METASTATIC BREAST CANCER
Clinical trials for HER2-POSITIVE METASTATIC BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE METASTATIC BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-POSITIVE METASTATIC BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug challenger takes on leading therapy for advanced breast cancer
Disease control Not yet recruitingThis study tests whether a new drug, trastuzumab rezetecan, works as well as or better than the current drug trastuzumab deruxtecan for women with advanced HER2-positive breast cancer that has worsened after previous treatment. About 100 women will be randomly assigned to one of …
Matched conditions: HER2-POSITIVE METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Spinal fluid may hold clues to breast cancer brain spread
Knowledge-focused Not yet recruitingThis study collects spinal fluid, blood, saliva, and tumor samples from 139 adults with HER2-positive or triple-negative breast cancer that has spread to other organs but not yet to the brain. Researchers will analyze these samples for tumor DNA that might predict when the cancer…
Matched conditions: HER2-POSITIVE METASTATIC BREAST CANCER
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 07:00 UTC
-
Kazakhstan cancer study to reveal Real-World treatment patterns
Knowledge-focused Not yet recruitingThis study will review medical records of about 240 adults in Kazakhstan with HER2-positive metastatic breast cancer to see how they were treated and how well they did. Researchers will look at treatments given in routine care (except one specific drug) and track outcomes like ho…
Matched conditions: HER2-POSITIVE METASTATIC BREAST CANCER
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC